V Square Quantitative Management LLC Cuts Stake in Hologic, Inc. (NASDAQ:HOLX)

V Square Quantitative Management LLC cut its stake in Hologic, Inc. (NASDAQ:HOLX) by 5.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,966 shares of the medical equipment provider’s stock after selling 387 shares during the quarter. V Square Quantitative Management LLC’s holdings in Hologic were worth $502,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. General Partner Inc. purchased a new position in Hologic in the fourth quarter valued at about $26,000. Groupama Asset Managment increased its position in shares of Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 2,999 shares during the last quarter. First Horizon Advisors Inc. increased its position in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the last quarter. Cromwell Holdings LLC increased its position in shares of Hologic by 330.2% during the third quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 416 shares during the last quarter. Finally, Covestor Ltd increased its position in shares of Hologic by 23.8% during the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after acquiring an additional 133 shares during the last quarter. 94.73% of the stock is owned by hedge funds and other institutional investors.

Hologic Stock Performance

Shares of HOLX stock opened at $63.24 on Friday. The company has a quick ratio of 3.03, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The business has a 50 day moving average of $71.04 and a two-hundred day moving average of $77.22. Hologic, Inc. has a 52 week low of $62.94 and a 52 week high of $84.67. The company has a market cap of $14.27 billion, a P/E ratio of 19.95, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, analysts anticipate that Hologic, Inc. will post 4.27 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HOLX. BNP Paribas raised Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Wolfe Research began coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating on the stock. UBS Group lifted their target price on Hologic from $84.00 to $90.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 5th. Royal Bank of Canada dropped their target price on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research report on Thursday, February 6th. Finally, Mizuho dropped their target price on Hologic from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Ten equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $85.77.

Insider Buying and Selling at Hologic

In other news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 1.88% of the stock is currently owned by insiders.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.